Back
 JBM  Vol.7 No.12 , December 2019
Possible Therapeutic Use of Bumetanide in the Treatment of Autism Spectrum Disorder
Abstract: Autism spectrum disorder (ASD) is a neurodevelopmental disorder. Autism Spectrum Disorder is diagnosed early on in a child’s life, anywhere from eighteen to twenty-four months. The disorder is characterized by variable degrees, by difficulties in nonverbal communication, verbal communication, social interaction, repetitive behaviors, and movement. The occurrence of ASD has been increasing globally, with the most recent prevalence studies indicating that they are present in six per one thousand children and one in every sixty-eight people of all ages, with a higher incidence among males, with a ratio of four to one. There is no specific target demographic for Autism Spectrum Disorder, nor is there a cure. Over the last few decades, there have been advancements in treating the symptoms associated with Autism Spectrum Disorder. Among the many different fields of research associated with Autism Spectrum Disorder, Bumetanide has shown to be a promising drug therapy for children suffering from Autism, treating specifically the behavioral symptoms associated with ASD. Bumetanide is forty times more potent than furosemide and is a loop diuretic mainly acting in the ascending limb of the loop of Henle. A clinical trial conducted found a decrease in the Childhood Autism Rating Scale (CARS) score, showing improvement in Autism Spectrum Disorder symptoms, such as repetitive behavior and initiating or participating in the social interaction.
Cite this paper: Kassem, S. and Oroszi, T. (2019) Possible Therapeutic Use of Bumetanide in the Treatment of Autism Spectrum Disorder. Journal of Biosciences and Medicines, 7, 58-67. doi: 10.4236/jbm.2019.712006.
References

[1]   Mayes, S.D., Calhoun, S.L., Mayes, R.D. and Molitoris, S. (2012) Autism and ADHD: Overlapping and Discriminating Symptoms. Research in Autism Spectrum Disorders, 6, 277-285.
https://doi.org/10.1016/j.rasd.2011.05.009

[2]   Faras, H., Al Ateeqi, N. and Tidmarsh, L. (2010) Autism Spectrum Disorders. Annals of Saudi Medicine, 295, 30-34.
https://doi.org/10.4103/0256-4947.65261

[3]   Bryson, S.E. and Smith, I.M. (1998) Epidemiology of Autism: Prevalence, Associated Characteristics, and Implications for Research and Service Delivery. Mental Retardation and Developmental Disabilities Research Reviews, 4, 97-103.
https://doi.org/10.1002/(SICI)1098-2779(1998)4:2<97::AID-MRDD6>3.0.CO;2-U

[4]   Schopler, E., Reichler, R. and DeVellis, R. (1980) Toward Objective Classification of Childhood Autism: Childhood Autism Rating Scale (CARS). Journal of Autism and Developmental Disorders, 10, 91-103.
https://doi.org/10.1007/BF02408436

[5]   Schopler, E., Reichler, R. and Rochen Renner, B. (1988) The Childhood Autism Rating Scale. Western Psychological Services.

[6]   Tachimori, H., Osada, H. and Kurita, H. (2003) Childhood Autism Rating Scale-Toky Version for Screening Pervasive Developmental Disorders. Psychiatry and Clinical Neuroscience, 57, 113-118.
https://doi.org/10.1046/j.1440-1819.2003.01087.x

[7]   Estes, A.M., Dawson, G., Sterling, L. and Munson, J. (2007) Level of Intellectual Functioning Predicts Patterns of Associated Symptoms in School-Age Children with Autism Spectrum Disorder. American Journal on Mental Retardation, 112, 439-449.
https://doi.org/10.1352/0895-8017(2007)112[439:LOIFPP]2.0.CO;2

[8]   Li, G., Jiang, W., Du, Y. and Rossbach, K. (2017) Intelligence Profiles of Chinese School Aged Boys with High-Functioning ASD and ADHD. Neuropsychiatric Disease and Treatment, 13, 1541.
https://doi.org/10.2147/NDT.S136477

[9]   Thorson, R.T. and Matson, J.L. (2012) Cutoff Scores for the Autism Spectrum Disorder Comorbid for Children (ASD-CC). Research in Autism Spectrum Disorders, 6, 556-559.
https://doi.org/10.1016/j.rasd.2011.07.016

[10]   Rogers, S.J. (2000) Diagnosis of Autism before the Age of 3. International Review of Research in Mental Retardation, 23, 1-31.
https://doi.org/10.1016/S0074-7750(00)80004-X

[11]   Zwaigenbaum, L., Bryson, S.E., Szatmari, P., Brian, J., Smith, I.M., Roberts, W., Vaillancourt, T. and Roncadin, C. (2012) Sex Differences in Children with Autism Spectrum Disorder Identified within a High-Risk Infant Cohort. Journal of Autism and Developmental Disorders, 42, 2585-2596.
https://doi.org/10.1007/s10803-012-1515-y

[12]   Sandra, M., Muratori, F., Cesari, A., Cavallaro, M.C., Paziente, A., Pecini, C., Grassi, C., Manfredi, A. and Sommario, C. (2005) Course of Autism Signs in the First Year of Life. Psychopathology, 38, 26-31.
https://doi.org/10.1159/000083967

[13]   Wiggins, L.D., Robins, D.L., Bakeman, R. and Adamson, L.B. (2009) Brief Report: Sensory Abnormalities as Distinguishing Symptoms of Autism Spectrum Disorders in Young Children. Journal of Autism and Developmental Disorders, 39, 1087-1091.
https://doi.org/10.1007/s10803-009-0711-x

[14]   Grandgeorge, M., Lemonnier, E., Degrez, C. and Jallot, N. (2014) The Effect of Bumetanide Treatment on the Sensory Behaviours of a Young Girl with Asperger Syndrome. BMJ Case Reports, 2014, bcr2013202092.
https://doi.org/10.1136/bcr-2013-202092

[15]   American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, American Psychiatric Association, Washington DC.

[16]   Garfin, D.G. and Lord, C. (1986) Communication as a Social Problem in Autism. In: Social Behavior in Autism, Springer, Boston, MA, 133-151.
https://doi.org/10.1007/978-1-4899-2242-7_7

[17]   Buffington, D.M., Krantz, P.J., McClannahan, L.E. and Poulson, C.L. (1998) Procedures for Teaching Appropriate Gestural Communication Skills to Children with Autism. Journal of Autism and Developmental Disorders, 28, 535-545.
https://doi.org/10.1023/A:1026056229214

[18]   Jang, J., Dixon, D.R., Tarbox, J. and Granpeesheh, D. (2011) Symptom Severity and Challenging Behavior in Children with ASD. Research in Autism Spectrum Disorders, 5, 1028-1032.
https://doi.org/10.1016/j.rasd.2010.11.008

[19]   Rellini, E., Tortolani, D., Trillo, S., Carbone, S. and Montecchi, F. (2004) Childhood Autism Rating Scale (CARS) and Autism Behavior Checklist (ABC) Correspondence and Conflicts with DSM-IV Criteria in Diagnosis of Autism. Journal of Autism and Developmental Disorders, 34, 703-708.
https://doi.org/10.1007/s10803-004-5290-2

[20]   ATT Medical Comorbidities in Autism Spectrum Disorders.
http://nationalautismassociation.org/pdf/medicalcomorbiditiesinasd2013.pdf

[21]   Mannion, A., Leader, G. and Healy, O. (2013) An Investigation of Comorbid Psychological Disorders, Sleep Problems, Gastrointestinal Symptoms and Epilepsy in Children and Adolescents with Autism Spectrum Disorder. Research in Autism Spectrum Disorders, 7, 35-42.
https://doi.org/10.1016/j.rasd.2012.05.002

[22]   Bauman, M.L. (2010) Medical Comorbidities in Autism: Challenges to Diagnosis and Treatment. Neurotherapeutics, 7, 320-327.
https://doi.org/10.1016/j.nurt.2010.06.001

[23]   Van Kammen, D.P. (1977) g-Aminobutyric Acid (Gaba) and the Dopamine Hypothesis of Schizophrenia. The American Journal of Psychiatry, 134, 138-143.

[24]   Cellot, G. and Cherubini, E. (2014) GABAergic Signaling as Therapeutic Target for Autism Spectrum Disorders. Frontiers in Pediatrics, 2, 70.
https://doi.org/10.3389/fped.2014.00070

[25]   Yip, J., Soghomonian, J.J. and Blatt, G.J. (2009) Decreased GAD65 mRNA Levels in Select Subpopulations of Neurons in the Cerebellar Dentate Nuclei in Autism: An in-Situ Hybridization Study. Autism Research, 2, 50-59.
https://doi.org/10.1002/aur.62

[26]   Oblak, A., Gibbs, T.T. and Blatt, G.J. (2009) Decreased GABAA Receptors and Benzodiazepine Binding Sites in the Anterior Cingulate Cortex in Autism. Autism Research, 2, 205-219.
https://doi.org/10.1002/aur.88

[27]   Pizzarelli, R. and Cherubini, E. (2011) Alterations of GABAergic Signaling in Autism Spectrum Disorders. Neural Plasticity, 2011, Article ID: 297153.
https://doi.org/10.1155/2011/297153

[28]   Tyzio, R., Nardou, R., Ferrari, D.C., Tsintsadze, T., Shahrokhi, A., Eftekhari, S., Khalilov, I., Tsintsadze, V., Brouchoud, C., Chazal, G. and Lemonnier, E. (2014) Oxytocin-Mediated GABA Inhibition during Delivery Attenuates Autism Pathogenesis in Rodent Offspring. Science, 343, 675-679.
https://doi.org/10.1126/science.1247190

[29]   éric, L., Degrez, C., Phelep, M., Tyzio, R., Josse, F., Grandgeorge, M., Hadjikhani, N. and Ben-Ari, Y. (2012) A Randomized Controlled Trial of Bumetanide in the Treatment of Autism in Children. Translational Psychiatry, 2, e202.
https://doi.org/10.1038/tp.2012.124

[30]   Ben-Ari, Y., Khalilov, I., Kahle, K.T. and Cherubini, E. (2012) The GABA Excitatory/Inhibitory Shift in Brain Maturation and Neurological Disorders. The Neuroscientist, 18, 467-486.
https://doi.org/10.1177/1073858412438697

[31]   Asbury, M.J., Gatenby, P.B.B., O’sullivan, S. and Bourke, E. (1972) Bumetanide: Potent New “Loop” Diuretic. British Medical Journal, 1, 211-213.
https://doi.org/10.1136/bmj.1.5794.211

[32]   Flamenbaum, W. and Friedman, R. (1982) Pharmacology, Therapeutic Efficacy, and Adverse Effects of Bumetanide, a New “Loop” Diuretic. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2, 213-222.
https://doi.org/10.1002/j.1875-9114.1982.tb03188.x

[33]   Du, L., Shan, L., Wang, B., Li, H., Xu, Z., Staal, W.G. and Jia, F. (2015) A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism. Journal of Child and Adolescent Psychopharmacology, 25, 585-588.
https://doi.org/10.1089/cap.2015.0045

[34]   Matson, J.L. (2007) Determining Treatment Outcome in Early Intervention Programs for Autism Spectrum Disorders: A Critical Analysis of Measurement Issues in Learning-Based Interventions. Research in Developmental Disabilities, 28, 207-218.
https://doi.org/10.1016/j.ridd.2005.07.006

[35]   Woo, C.C. and Leon, M. (2013) Environmental Enrichment as an Effective Treatment for Autism: A Randomized Controlled Trial. Behavioral Neuroscience, 127, 487.
https://doi.org/10.1037/a0033010

[36]   Volkmar, F.R. and Cohen, D.J. (1991) Comorbid Association of Autism and Schizophrenia. The American Journal of Psychiatry, 148, 1705-1707.

[37]   Amir, R.E., Van den Veyver, I.B., Wan, M., Tran, C.Q., Francke, U. andZoghbi, H.Y. (1999) Rett Syndrome Is Caused by Mutations in X-Linked MECP2, Encoding Methyl-CpG-Binding Protein 2. Nature Genetics, 23, 185.
https://doi.org/10.1038/13810

[38]   Kumar, R.A. and Christian, S.L. (2009) Genetics of Autism Spectrum Disorders. Current Neurology and Neuroscience Reports, 9, 188-197.
https://doi.org/10.1007/s11910-009-0029-2

[39]   Gillberg, C. (1987) Autistic Symptoms in Rett Syndrome: The First Two Years According to Mother Reports. Brain and Development, 9, 499-501.
https://doi.org/10.1016/S0387-7604(87)80072-4

[40]   Belmonte, M.K. and Bourgeron, T. (2006) Fragile X syndrome and Autism at the Intersection of Genetic and Neural Networks. Nature Neuroscience, 9, 1221.
https://doi.org/10.1038/nn1765

[41]   Harris, S.W., Hessl, D., Goodlin-Jones, B., Ferranti, J., Bacalman, S., Barbato, I., Tassone, F., Hagerman, P.J., Herman, K. and Hagerman, R.J. (2008) Autism Profiles of Males with Fragile X Syndrome. American Journal on Mental Retardation, 113, 427-438.
https://doi.org/10.1352/2008.113:427-438

[42]   Ward, A. and Heel, R.C. (1984) Bumetanide. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use. Drugs, 28, 426-464.
https://doi.org/10.2165/00003495-198428050-00003

[43]   Moore, Y.E., Conway, L.C., Brandon, N.J., Deeb, T.Z. and Moss, S.J. (2019) Developmental Regulation of KCC2 Phosphorylation Has Long-Term Impacts on Cognitive Function. Frontiers in Molecular Neuroscience, 12, 173.
https://doi.org/10.3389/fnmol.2019.00173

[44]   Schulte, J.T., Wierenga, C.J. and Bruining, H. (2018) Chloride Transporters and GABA Polarity in Devel-opmental, Neurological and Psychiatric Conditions. Neuroscience & Biobehavioral Reviews, 90, 260-271.
https://doi.org/10.1016/j.neubiorev.2018.05.001

[45]   Holmes, G.L., Tian, C., Hernan, A.E., Flynn, S., Camp, D. and Barry, J. (2015) Alterations in Sociability and Functional Brain Connectivity Caused by Early-Life Seizures Are Prevented by Bumetanide. Neurobiology of Disease, 77, 204-219.
https://doi.org/10.1016/j.nbd.2015.02.015

[46]   Oh, S.W. and Han, S.Y. (2015) Loop Diuretics in Clinical Practice. Electrolytes & Blood Pressure, 13, 17-21.
https://doi.org/10.5049/EBP.2015.13.1.17

[47]   Eades, S.K. and Christensen, M.L. (1998) The Clinical Pharmacology of Loop Diuretics in the Pediatric Patient. Pediatric Nephrology, 12, 603-616.
https://doi.org/10.1007/s004670050514

[48]   Lemonnier, E., Villeneuve, N., Sonie, S., Serret, S., Rosier, A., Roue, M., Brosset, P., Viellard, M., Bernoux, D., Rondeau, S. and Thummler, S. (2017) Effects of Bumetanide on Neurobehavioral Function in Children and Adolescents with Autism Spectrum Disorders. Translational Psychiatry, 7, e1056.
https://doi.org/10.1038/tp.2017.10

[49]   Sullivan, J.E., Witte, M.K., Yamashita, T.S., Myers, C.M. and Blumer, J.L. (1996) Analysis of the Variability in the Pharmacokinetics and Pharmacodynamics of Bumetanide in Critically Ill Infants. Clinical Pharmacology & Therapeutics, 60, 414-423.
https://doi.org/10.1016/S0009-9236(96)90198-8

[50]   Hadjikhani, N., Zurcher, N.R., Rogier, O., Ruest, T., Hippolyte, L., Ben-Ari, Y. and Lemonnier, E. (2015) Improving Emotional Face Perception in Autism with Diuretic Bumetanide: A Proof-of-Concept Behavioral and Functional Brain Imaging Pilot Study. Autism. The International Journal of Research and Practice, 19, 149-157.
https://doi.org/10.1177/1362361313514141

 
 
Top